Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Commercial Paper by Year
Commercial Paper — Year-end principal outstanding ($M) ($M)
Pfizer Commercial Paper: $0M in FY2025, down 100.0% from a year earlier. That is the lowest of the 10 years on record here.
Latest, FY2025
0
Period ended Dec 31, 2025
Change on a year earlier
-100.0%
2,453 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-K Financial Instruments Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Commercial Paper — Year-end principal outstanding ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | -100.0% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 2,453 | -69.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 7,965 | – | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 0 | -100.0% | Form 10-K (filed 2022-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 556 | -96.0% | Form 10-K (filed 2022-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 13,915 | +348.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 3,100 | -49.2% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 6,100 | +5.2% | Form 10-K (filed 2019-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 5,800 | – | Form 10-K (filed 2018-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Commercial Paper ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/comm-paper-ann
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.